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The renin-angiotensin system (RAS) has long been a known endocrine system that is
involved in regulation of blood pressure and fluid balance. Over the last two decades,
evidence has accrued that shows that there are local RAS that can affect cellular activity,
tissue injury, and tissue regeneration. There are locally active ligand peptides, mediators,
receptors, and signaling pathways of the RAS in the bone marrow (BM). This system is
fundamentally involved and controls the essential steps of primitive and definitive blood-
cell production. Hematopoiesis, erythropoiesis, myelopoiesis, thrombopoiesis, formation
of monocytic and lymphocytic lineages, as well as stromal elements are regulated by the
local BM RAS. The expression of a local BM RAS has been shown in very early, primitive
embryonic hematopoiesis. Angiotensin-converting enzyme (ACE-1, CD143) is expressed on
the surface of hemangioblasts and isolation of the CD143 positive cells allows for recovery
of all hemangioblast activity, the first endothelial and hematopoietic cells, forming the mar-
row cavity in the embryo. CD143 expression also marks long-term blood-forming CD34+
BM cells. Expression of receptors of the RAS is modified in the BM with cellular matu-
ration and by injury. Ligation of the receptors of the RAS has been shown to modify the
status of the BM resulting in accelerated hematopoiesis after injury.The aim of the present
review is to outline the known functions of the local BM RAS within the context of primitive
and definitive hematopoiesis as well as modification of BM recovery by administration of
exogenous ligands of the RAS. Targeting the actions of local RAS molecules could repre-
sent a valuable therapeutic option for the management of BM recovery after injury as well
as neoplastic disorders.
Keywords: renin-angiotensin system, bone marrow, stem cells, angiotensin 1-7, CD143, hematopoiesis,
myelosuppression
INTRODUCTION
The first evidence that there are effects of the renin-angiotensin
system (RAS) on bone marrow (BM) and hematopoiesis resulted
from clinical use of therapeutics that modify the produc-
tion/action of angiotensin II (A-II). From the early 1980s, studies
showed that there was a small reduction in hematocrit in patients
receiving angiotensin-converting enzyme (ACE) inhibitors, par-
ticularly with enalapril (1). Further, enalapril use was associated
with anemia in renal transplant patients as well as normal rats
(2, 3). Prior to the use of Epogen to treat anemia in patients
on long-term dialysis, the majority of patients receiving captopril
developed dose dependent anemia that was reversed upon discon-
tinuation of captopril treatment (4). Erythrocytosis occurs after
renal transplantation. In these patients, there are anecdotal reports
and studies showed that ACE inhibitors, and angiotensin receptor
blockers (ARBs) reduce hematocrit levels in post-transplantation
erythrocytosis (5–7). In two prospective studies, a reduction in
hemoglobin concentrations was reported in hypertensive patients
treated with ARBs compared with patients treated with β-blockers
or calcium antagonists (8,9). These observations led to the hypoth-
esis in the mid-1990s that there is a local RAS in the BM that is
involved in the regulation of hematopoiesis. These early obser-
vations were thought to be the result of increased levels of an
inhibitor of hematopoiesis, the acetylated tetrapeptide AcSKPD,
that is hydrolyzed by ACE or due to interactions of the RAS
directly with the hematopoietic system. Activation of the RAS
was shown to enhance erythropoietin production (10). Similarly,
administration of ACE inhibitors reduces plasma erythropoietin
levels, exacerbating anemia (11). Administration of A-II to patients
after hemorrhage leads to an increase in plasma erythropoietin
levels (12). This work was recently reviewed by Vlahakos (13).
All of these studies suggested that the RAS directly modifies
erythropoiesis.
THE RENIN-ANGIOTENSIN SYSTEM IN BONE MARROW AND
HEMATOPOIESIS
RAS COMPONENTS AND RAS KNOCKOUT MICE
Research over the last few decades has confirmed the presence
of a local, integrated RAS within several tissues. Every known
component of the RAS is contained within BM cells, including
mRNA for angiotensinogen, renin,ACE,AT1a,AT2, Mas, and ACE2
[(14, 15), Figure 1]. Transgenic mice carrying both human renin
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FIGURE 1 |There is substantial evidence for a key role for the RAS both primitive and definitive hematopoiesis as well as the development of
hematopoietic progenitor cells. Every component of the RAS is present in the local environment of the bone marrow.
and angiotensinogen genes have increased hematocrits in animals
intact for AT1, but not AT1 null animals (16). Further, mice that are
deficient in individual components of the RAS have been shown to
have impairment of hematopoiesis. Direct evidence for the role of
RAS in hematopoiesis independent of ACE hydrolysis of AcSDKP
came from animal models (ACE Knock out (KO)) and in vitro
studies. In one strain of ACE-KO mice, there were increases in
circulating levels of AcSDKP that was accompanied by a 35 mm
Hg decrease in blood pressure, renal insufficiency, and unexpected
normocytic anemia associated with an increase in circulating ery-
thropoietin in response to anemia (17). A similar anemia was also
present in another strain of genetically engineered mice express-
ing a truncated form of secreted ACE (18). In these mice, plasma
ACE activity was reduced without evidence of renal insufficiency
indicating that the anemia was not the consequence of the renal
failure, but the result of a reduction in red-cell mass. The degree
of anemia in these two mouse strains was similar, despite a signifi-
cant difference between plasma AcSDKP levels. This finding again
suggests that AcSDKP was not the primary cause of anemia. To
evaluate the role of A-II in hematopoiesis, hematocrit was mea-
sured before and after A-II infusion for 2 weeks. The hematocrit
level was corrected in ACE-deficient mice to near wild-type lev-
els, strongly suggesting that the lack of A-II in these mice was the
direct cause of the anemia. Further, several studies have shown
that A-II, in the presence of erythropoietin, will increase erythroid
progenitors in vitro (19–21).
In another strain of ACE-KO mice, abnormalities in
myelopoiesis were seen. These abnormalities were character-
ized by increased BM myeloblasts and myelocytes, as well as
extramedullary myelopoiesis (22). Further, neutrophils (banded
and segmented) and erythroid elements were reduced approxi-
mately one third in the BM. Increases in splenic CD11b+Gr1dim
cells in these mice together with the increase in BM myelocytes
indicate a block in myeloid differentiation at the post-GMP stage
of development. A-II, through AT1, stimulates myeloid differen-
tiation and function. In these mice, plasma levels of A-II were
decreased by approximately 10-fold. Part of these effects was
thought to be due to up-regulation of C/EBPα, a central transcrip-
tion factor of myelopoiesis. Macrophages derived from ACE-KO
mice had depressed C/EBPα expression and treatment with A-II
restored expression of this transcription factor (23). Function of
the myeloid cells that did develop in these mice was also impaired
(22). Peritoneal macrophages from ACE-KO mice were deficient
in the production of effector molecules, such as tumor necro-
sis factor-α, interleukin-12p40, and CD86 when stimulated with
lipopolysaccharide and interferon-γ. ACE-KO mice were more
susceptible to Staphylococcus aureus infection showing a reduction
in host resistance.
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RAS IN HEMATOPOIESIS
Observations in KO mice provides evidence that points to a
significant role for the RAS in the regulation of hematopoiesis
and the development of hematopoietic progenitor cells (23–25).
The central role of the RAS in regulating early hematopoiesis
has been the focus of several reviews (23, 26–28). In addi-
tion to reduced/delayed hematopoiesis in ACE-KO mice, is the
observation that expression of ACE demarcates early events in
hematopoiesis both in the fetus and the adult. The earliest marker
for the isolation of hemangioblasts, hematopoietic stem cells, and
epidermal stem cells is ACE1 (CD143) (26, 29–31). ACE1 was
also shown to be expressed in all presumptive and developing
blood-forming tissues of the human embryo and fetus: para-aortic
splanchnopleura, yolk sac, aorta-gonad-mesonephros, liver, and
BM (32). This is expanded upon further below.
The role of ACE and A-II in adult hematopoiesis led to
investigations of the possible role of the RAS in primitive
hematopoiesis. The first studies were done in avian mod-
els. In these models, primitive hematopoiesis occurs prior to
intra-embryonic hematopoiesis (33). Extra-embryonic blood
islands differentiate into endothelial and hematopoietic cells (34).
ACE gene expression and protein was detected in the yolk-sac
endoderm before the beginning of blood-island differentiation,
when the circulation is not yet established between the yolk sac
and the embryo (35). At 30 h development in the avian model,
the other components of the RAS, renin and angiotensinogen,
were present in the vicinity of the blood islands, which strongly
suggests a role for the RAS in erythropoiesis. Administration of
ACE inhibitors or ARBs to 2-day-old embryos resulted in a sig-
nificantly lower hematocrit in treated embryos than in control
embryos. These results show that the RAS modulates blood-island
differentiation during the primitive yolk-sac erythropoiesis (35).
Since these observations, studies were done to evaluate the expres-
sion of the RAS components in mammalian embryos, especially
in humans. These studies confirm a role for RAS in mammalian
primitive hematopoiesis.
Studies in mammalian hematopoiesis were facilitated by the
development of the monoclonal antibody, BB9. BB9 is specific for
the somatic isoform of surface ACE (CD143). As outlined above,
the first observation was that a protein immunologically similar to
ACE is expressed in the embryonic para-aortic splanchnopleura,
where blood-cell progenitors are generated (36), suggesting that
a local RAS exists within the intra-embryonic sites of definitive
hematopoiesis in the mammal. ACE expression was also identi-
fied emerging hematopoietic cells from both CD34− and CD34+
areas of human yolk sac, intra-embryonic splanchnopleura, and
hemogenic endothelium of the aorta-gonad-mesonephros region
and fetal liver (FL) (29). The embryonic pattern of human ACE
expression is consistent with a dorsal emigration of ACE+CD34−
hemangioblasts from the para-aortic splanchnopleura, and subse-
quent colonization of the ventral aspect of the dorsal aorta to give
rise to CD34+ hemogenic endothelial cells. Using BB9, a primitive
subset of CD34+ multi-lineage hematopoietic stem cell that could
engraft NOD SCID mice was identified in adult BM, mobilized
peripheral blood, and umbilical cord blood (37).
In 2008, Zambidis and others reported that ACE is a
novel marker for identifying hemangioblasts differentiating from
human embryonic stem cells (hESC). Cells developed from
hESC that expressed ACE (ACE+CD45−CD34±) were heman-
gioblasts that were progenitors for not only endothelium but
also both primitive and definitive human lymphohematopoietic
cells. Thrombopoietin and basic fibroblast growth factor were
identified as critical factors for the proliferation of human heman-
gioblasts. Furthermore, ACE and receptors for A-II, AT1, and AT2
directly regulated hemangioblast expansion and differentiation.
ACE enzymatic activity was required for hemangioblast expansion.
Further, differentiation toward either endothelium or multipotent
hematopoietic progenitors is modified by exposure to AT1 and AT2
antagonists. In this study, AT2 function was necessary for expan-
sion of hemangioblast colonies into multipotent hematopoietic
progenitors; whereas blockade of AT2 by PD 123319 abolished
hematopoietic differentiation and sent the hemangioblasts toward
an endothelial lineage. Conversely, inhibition of AT1 by losar-
tan augmented differentiation of hemangioblast colonies into
multipotent hematopoietic progenitors.
The influence of modification of the RAS in mesenchymal
stem cells (MSC) has also been evaluated (38). Expression of
the AT1 receptor in MSC was initially observed in 2000 (21).
MSC can be differentiated into a number of cell types, includ-
ing those involved in fibrosis and adipogenesis. Differentiation
of human MSCs into adipocytes resulted in increased expres-
sion of renin and AT2 and a decrease in angiotensinogen and
ACE expression with a net increase in endogenous cellular
A-II production. Incubation of MSC with A-II with and with-
out an AT1 antagonist inhibited adipogenesis, whereas A-II and
an AT2 antagonist abolished the inhibition of adipogenesis. MSC
can also be differentiated into renin-producing cells in the kid-
ney, juxtaglomerular cells (39, 40). Increased numbers or activa-
tion of these cells is important in the initiation of pathological
effects of chronic overexpression of A-II through increase pro-
duction of renin, the rate-limiting enzyme in the production of
A-II.
RAS: A NOVEL TARGET IN BONE MARROW INJURY AND
MYELOSUPPRESSION
Multi-lineage suppression of BM progenitors occurs following
myelosuppressive chemotherapy, as well as radiation, resulting in
cytopenias of their formed elements in the peripheral circulation.
Myelosuppression and the more severe myeloablation (requiring
hematopoietic stem cell support for recovery) can be the result
of exposure to chemotherapy or radiation therapy for neoplas-
tic disease, to diagnostic radiation exposure or due to radiation
exposure as a result of nuclear accident or terrorism. The manifes-
tations of myelosuppression include anemia, thrombocytopenia,
lymphopenia, and neutropenia. In the setting of chemo or radi-
ation therapy, myelosuppression is often managed with a delay
and/or a dose reduction in the next scheduled cycle of chemother-
apy, to allow recovery of BM and circulating formed elements.
However, such modifications to the chemotherapy regimen result
in lower relative dose intensity (the ratio of delivered dose inten-
sity to planned dose intensity). Numerous studies, particularly in
breast cancer and NHL, have established that long-term survival
may be compromised if the total dose or relative dose intensity
falls below a threshold value (41–45).
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Prolonged or severe myelotoxic effects may reflect a diminished
hematopoietic reserve, which may occur with aging, age-related
comorbidity, intensive chemotherapy, combined radiation ther-
apy/radiation therapy, or previous exposures to myelosuppressive
therapies. Therefore the risk of myelosuppression leading to mod-
ifications of chemotherapy is higher in older patients and patients
with recurrent neoplasms. Even when the chemotherapy regimen
is relatively benign and myelotoxicity is limited, elderly patients
tend to be more vulnerable than younger patients (46).
The most widely utilized hematopoietic stimulants (erythro-
poietin, filgrastim, or sargramostim) act on later stage precursors
and usually induce proliferation, differentiation, and mobilization
of single cell lineages from the BM into the peripheral circula-
tion. For this reason, they do not individually impact chronic
and progressive multi-lineage cytopenias that commonly occur
after myelosuppression. This finding suggests that a treatment
which stimulates proliferation and differentiation of hematopoi-
etic stem/progenitor cells should reduce incidence of clinically
significant cytopenias.
ANGIOTENSIN 1-7 AS A THERAPEUTIC IN BONE MARROW
RECOVERY
Because of the increased sensitivity of immature cells compared
with more mature cells of a given cellular lineage to the prolifera-
tive effects of angiotensin peptides, therapeutic opportunities exist
to enhance tissue regeneration, particularly the repair of injuries
in the BM associated with chemotherapy and radiation. Poten-
tial populations include cancer patients receiving antineoplastic
or radiation therapy with myelosuppressive side effects, stem cell
transplant patients after myeloablative conditioning, patients with
conditions resulting in ineffective myelopoiesis and apoptosis of
hematopoietic progenitors and individuals exposed to nuclear
radiation.
Peptides of the RAS are potent stimulators of progenitor cell
proliferation (21, 24, 47–49). RAS receptors are increased after
injury (50–53). Preclinical studies have shown that hematopoietic
progenitor cells are sensitive to Angiotensin 1-7 [A(1-7)] stimula-
tion and the effect of this biologically active member of the endoge-
nous protective arm of the RAS in vivo is most robust after injury
(24, 47–49, 54). A(1-7) has multi-lineage effects on hematopoietic
progenitors in vitro and in vivo (24, 48, 52, 54–56) and is under-
going clinical development for the treatment of myelosuppression
and to increase hematopoietic stem cell transplantation.
Angiotensin 1-7 treatment following 5-fluorouracil (5FU)
administration resulted in a higher number of progenitors in
the myeloid, megakaryocyte, and erythroid lineage in murine BM
(48). However, the most extensive preclinical data set with A(1-7)
is following myelosuppression due to total body irradiation (TBI)
(24, 47). An early increase and sustained expansion in early mixed,
myeloid, erythroid, and megakaryocytic progenitors was observed
in A(1-7)-treated animals compared to controls. At 30 days after
TBI, A(1-7) treatment increased early mixed progenitors (three-
to fivefold), megakaryocyte (two- to threefold), myeloid (three- to
sixfold), and erythroid (two- to fivefold) progenitors in the BM
and reduced radiation-induced thrombocytopenia (RIT) (up to
twofold). Consistent with clinical results below, it is important
to initiate treatment with this peptide once the damage resulting
from the myelotoxic exposure has ceased. For example, improve-
ment in BM progenitors following TBI were better at higher doses
of A(1-7) when drug was initiated at 48 h post-TBI as opposed to
24 h post-TBI.
In the A(1-7)-treated animals, the nadir in BM progenitors was
not as low as in the control animals and accelerated recovery was
observed. The multi-lineage BM response resulted in platelet and
white blood-cell recovery after TBI (24, 47). Initiation of A(1-7)
treatment could be delayed up to 5 days following TBI with con-
tinued improvement of hematopoietic recovery both in the BM
and formed elements in the peripheral blood (24).
It is hypothesized that A(1-7) acts to stimulate hematopoiesis
through the Mas receptor. The expression of Mas in normal BM
is low. However, as with injuries to other tissues, Mas expression
in hematopoietic progenitors in the BM is increased by myelosup-
pression (52). The ability of A(1-7) to accelerate BM recovery was
blocked by administration of the Mas antagonist, A779; whereas
losartan, an antagonist of AT1 (the constitutively expressed recep-
tor for A-II) did not (24, 55). In order to ascertain the receptor that
A(1-7) acts through to stimulate hematopoietic recovery, antago-
nists of the type I receptor (losartan), type 2 receptor (PD123319),
or Mas receptor were co-administered with A(1-7). Administra-
tion of the antagonists had no effect on the recovery of platelets
while the Mas antagonist blocked the acceleration of platelet recov-
ery by A(1-7) (55). Of interest, RAS receptors, AT1, AT2, and Mas,
are G coupled protein receptors that are capable of distinguishing
small changes in peptide sequence and provide novel targets for
modulation of hematopoiesis.
The kinetics of changes in hematopoietic progenitors in BM
with A(1-7) treatment after TBI were evaluated. There was an
early increase (up to fivefold by Day 7) in myeloid and erythroid
progenitors that continued to expand more rapidly than in control
animals through Day 14. The number of megakaryocytes in the
BM was measured by CD41+ (platelet glycoprotein IIb of IIb/IIIa
complex) expression. In contrast to myeloid and erythroid progen-
itors, the nadir for megakaryocyte number after TBI was Day 8. In
control animals, recovery did not start until Day 14 and plateaued
at Day 22. In the A(1-7)-treated animals, the nadir was not as low
as the control animals and recovery was seen at Day 10. By Day 14,
the megakaryocyte number doubled in the treated animals and
was comparable to that observed in the control animals at Day
22. After Day 22 recovery in the control animals reached a plateau,
and recovery of the number of megakaryocytes continued through
Day 30 (the last time point measured) in the animals treated with
A(1-7). Changes were also observed in thrombopoietin, a key reg-
ulator in platelet generation, production, and utilization that are
consistent with these observations. At the nadir of platelet levels,
there was increased utilization of thrombopoietin. However, later,
when megakaryocyte levels and maturity were comparable to non-
irradiated controls in A(1-7)-treated animals, there was an increase
in circulating thrombopoietin levels. These data suggest that the
primary action of A(1-7) is at the level of the progenitor cell.
In all studies with repeat bleeding, a nadir was found in platelet
number after TBI even with A(1-7) treatment. However, the nadir
was diminished at an early time point. It is hypothesized that the
mechanism by which this occurs is A(1-7) reducing consump-
tion of platelets as well as increasing their production. Platelet
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consumption occurs through bleeding at sites of injury due to
radiation (such the gastrointestinal tract or the cerebral cortex) or
through the formation of thrombus (in part due to endothelial
dysfunction). As will be shown below, A(1-7) reduced mucosal
injury. Further, A(1-7) reduces oxidative stress after injury, which
would contribute to endothelial dysfunction.
SYNERGY ANDMULTI-LINEAGE EFFECTS AFTER COMBINING
A(1-7) WITH COLONY STIMULATING FACTORS
Combining A(1-7) with commonly used growth factors [filgrastim
(Neupogen®), and erythropoietin (Epogen®)], in C57Bl/6 mice
post-chemotherapy increased the numbers of BM progenitor cells
and formed elements in the peripheral circulation (52, 57). A(1-
7) administered in combination with suboptimal doses of Neu-
pogen® throughout the post-myelosuppressive interval increased
the number of progenitors and circulating WBC concentration to
a greater extent than occurred with either drug alone (52). These
studies indicate that the A(1-7) effects on progenitors can enhance
the concentration of formed elements in the peripheral blood in
the presence of appropriate differentiating agents.
Administration of A(1-7) with filgrastim (the latter given only
3 days starting at the white blood-cell nadir) decreased 10-fold
the amount of filgrastim needed for optimal recovery of BM
progenitors (CFU-GEMM, CFU-GM, CFU-Meg, and BFU-E) and
circulating formed elements (WBC, platelets). In addition to
the synergistic effects of combining A(1-7) and Neupogen on
white blood-cell and neutrophil recovery, combining these thera-
pies increased platelet concentrations above those observed with
A(1-7) alone.
In addition, combination of A(1-7) with erythropoietin slightly
increased (not significantly) red blood-cell concentrations above
those achieved by erythropoietin alone. However, in this model,
A(1-7) or A(1-7) in combination with erythropoietin increased
all erythroid progenitors with the largest effect on early ery-
throid progenitors (immature BFU-E). As before with Neupogen,
combining A(1-7) with Epogen has hematological effects outside
of the erythroid lineage in that the concentration of circulating
neutrophils was increased with this combination. In conclusion,
filgrastim and erythropoietin acted synergistically with A(1-7)
to increase the concentration of myeloid, megakaryocytic, and
erythroid progenitor cells in the BM following chemotherapy, sug-
gesting that A(1-7)’s multi-lineage effect on early progenitors in
the marrow facilitates proliferation in response to lineage specific
growth factors.
CLINICAL DEVELOPMENT OF A(1-7) FOR HEMATOPOIESIS
Multi-lineage suppression of marrow precursors occurs follow-
ing myelosuppressive radiotherapy and chemotherapy resulting
in cytopenias of one or more of the mature formed elements of
blood. As described above, preclinical studies of A(1-7) demon-
strated an increase in multiple lineages of early hematopoietic
precursors from the BM and the peripheral blood of mice, and
in vitro exposure of cells from human cord blood.
A Phase I/IIa prospective, blinded, randomized, dose-escalation
study of a clinical formulation of A(1-7) was conducted in breast
cancer subjects receiving three cycles of adjuvant doxorubicin and
cyclophosphamide following surgical tumor reduction (54). The
study compared the effects of up to 100µg/kg of A(1-7) to fil-
grastim (n= 5) as a comparator arm for safety and response
variables. A(1-7) was found to be safe and was well-tolerated.
No dose-limiting toxicity was observed following subcutaneous
administration of up to 100µg/kg of A(1-7) for periods of up to
14 days. No A(1-7)-treated patients experienced any NCI Grade
1–4 platelet reductions compared to 60% of the controls. Fur-
ther, patients had a lower incidence of lymphopenia, anemia, and
mucositis. Additionally, following the completion of the third cycle
of chemotherapy, recovery of hemoglobin, lymphocytes, leuko-
cytes, neutrophils, and platelets was superior in A(1-7)-treated
subjects. A(1-7) also reduced filgrastim use, as well as development
of mucositis. Further, anemia was reduced even though two of the
five control patients and one of 15 treated patients [in the low-
est A(1-7) dose group] received erythropoietin for anemia. There
were no A(1-7) treatment related serious adverse events (SAE)
reported in this study.
A Phase 2b study evaluating the safety and efficacy of a
clinical formulation of A(1-7) in reducing the incidence and
severity of thrombocytopenia in subjects receiving a combina-
tion of gemcitabine and platinum therapy for ovarian carci-
noma for six cycles was conducted. The primary endpoint of
this study was the severity and incidence of thrombocytope-
nia as determined by the number of chemotherapy cycles dur-
ing which the platelet count was below 50,000/mm3. A sig-
nificant reduction of Grade 4 thrombocytopenia was seen in
the 100µg/kg group (56). In addition, there was a significant
increase in the maximal percent increase in platelet count and
delivery of scheduled chemotherapy dose on time in subjects
treated with 100µg/kg/day versus placebo-treated control. Main-
tenance of the scheduled chemotherapy at the desired dose has
been linked with improved tumor control and long-term sur-
vival. No dose-limiting toxicity was observed during the course of
the study and no investigational product-related SAEs or deaths
occurred.
Benefit: data from clinical studies confirm and extend the results
seen in preclinical models. These findings are consistent with the
species homology of A(1-7). Overall, the observed increase in
sensitivity of immature stem/early progenitor cells to the pro-
liferative and regenerative effects of angiotensin peptides offers
unique therapeutic opportunities including significantly enhanced
hematopoietic recovery after chemotherapy as well as the potential
to facilitate BM regeneration.
CONCLUSION
A central role for the RAS in BM development and recovery has
been the focus of two decades of research. ACE1 is a pivotal
component in hematopoiesis in that expression marks early cells
involved in primitive and definitive hematopoiesis. Reduction of
ACE activity either through ACE inhibitors or ACE-KO results in
abnormal hematopoiesis,particularly in the erythroid and myeloid
lineages. While all components of the RAS are expressed in BM
cells, fetal receptors of RAS, such as AT2, are expressed only on
very early progenitors and are down regulated during differenti-
ation. However, injury to the BM or myelosuppression modified
RAS expression and up-regulates receptors of the protective RAS,
Mas, and AT2.
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Preclinical studies of A(1-7) suggest a potential to increase mul-
tiple lineages of early hematopoietic precursors cultured from the
BM and the peripheral blood of mice. These studies have shown an
increase in the number of progenitors and formed elements in the
peripheral blood after treatment with A(1-7). Studies in murine
models show that A(1-7) prevents or mitigates thrombocytopenia
following myelotoxic chemotherapy. This benefit is supported by
clinical data from multiple trials which shows decreased incidence
of thrombocytopenia and increased BM recovery in A(1-7) treated
patients following myelotoxic chemotherapy. Additional preclini-
cal data in TBI models show that A(1-7) treatment also prevents
or mitigates thrombocytopenia even when treatment initiation is
delayed up to 48 h post exposure. It is anticipated that demon-
stration of the benefit of A(1-7) administration in these models
will be translatable to humans for the indication of mitigating
thrombocytopenia following TBI.
Clinical studies also suggest that exposure to A(1-7) maintains
the pre-chemotherapy health of the BM by restoring the various
hematopoietic parameters to baseline values and allows the main-
tenance of chemotherapy dose intensity (54, 56). This consistent
A(1-7)-mediated return to baseline hematopoietic values may be
due to an increase in the number of hematopoietic progenitor
cells thereby pharmacologically replenishing the hematopoietic
system.
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